RECENT UPDATE ON PRONIOSOMAL GEL AS TOPICAL DRUG DELIVERY SYSTEM

  • Jampala Rajkumar Department of Pharmaceutics, Gitam Institute of Pharmacy, Gitam (Deemed to be University), Rushikonda, Visakhapatnam - 530 045, Andhra Pradesh, India.
  • Radha Gv Department of Pharmaceutics, Gitam Institute of Pharmacy, Gitam (Deemed to be University), Rushikonda, Visakhapatnam - 530 045, Andhra Pradesh, India.
  • Trideva Sastri K Department of Pharmaceutics, Gitam Institute of Pharmacy, Gitam (Deemed to be University), Rushikonda, Visakhapatnam - 530 045, Andhra Pradesh, India.
  • Sadhana Burada Department of Pharmaceutics, Gitam Institute of Pharmacy, Gitam (Deemed to be University), Rushikonda, Visakhapatnam - 530 045, Andhra Pradesh, India.

Abstract

An existence of transdermal delivery tool, proniosomal gel, has established to showed remarkable development for lipophilic/hydrophilic drugs over additional formulations. Newer drugs of lipophilic nature emerge poor bioavailability, irregular absorption, and pharmacokinetic changes. Therefore, this novel drug delivery system has been proved advantageous over other oral and topical delivery of drug candidates to bypass such disruption. This proniosomal gel basically is a compact semi-solid liquid crystalline (gel) composed of non-ionic surfactants easily formed on dissolving the surfactant in a minimal amount of acceptable solvent and the least amount of aqueous phase and phosphate buffer. Topical application of gel under occlusive condition during which they are converted into nisomes due to hydration by water in the skin present itself. Proniosomal gels are typically present in transparent, translucent, or white semisolid gel texture, which makes them physically stable throughout storage and transport. This review provides an important overview of the preparation, formulation, evaluation, and application of proniosome gel as a drug delivery carrier.

Keywords: Vesicular drug delivery, Proniosomal gel, Non-ionic surfactants, Coacervation phase separation, Topical drug delivery.

Author Biography

Jampala Rajkumar, Department of Pharmaceutics, Gitam Institute of Pharmacy, Gitam (Deemed to be University), Rushikonda, Visakhapatnam - 530 045, Andhra Pradesh, India.

PHARMACEUTICS

Dept of PHARMACY

References

1. Bender GA. A history of pharmacy in pictures-great moments in pharmacy. J Am Pharm Assoc 2002;42:170-82.
2. Yuksel N, Bayindir ZS, Aksakal E, Ozcelikay AT. In situ niosome forming maltodextrin proniosomes of candesartan cilexetil: In vitro and in vivo evaluations. Int J Biol Macromol 2016;82:453-63.
3. Kumar S, Singh P. Various techniques for solubility enhancement: An overview. Pharma Innov 2016;5:23-8.
4. Weissig V, Lizano C, Torchilin VP. Selective DNA release from DQAsome/DNA complexes at mitochondria-like membranes. Drug Deliv 2000;7:1-5.
5. Abhishek VG, Salunhe Ks, Chaudhari SR. Review on self-micro-emulsifying drug delivery system. Am J PharmTech Res 2015;5:50-66.
6. Vemula VR, Lagishetty V, Lingala S. Solubility enhancement techniques. Int J Pharm Sci Rev Res 2010;5:41-51.
7. Biju SS, Talegaonkar S, Mishra PR, Khar RK. Areview onvesicular systems. Indian J Pharm Sci 2006;68:141-53.
8. Ghulaxe C, Verma R. A review on transdermal drug delivery system. Pharm Innov 2015;4:37-43.
9. Singh Malik D, Mital N, Kaur G. Topical drug delivery systems: A patent review. Expert Opin Ther Pat 2016;26:213-28.
10. Khan R, Irchhaiya R. Noisome a potential tool for novel drug delivery. J Pharm Investig 2016;46:195-204.
11. Saini V, Bala NM, Jhawat V, Kamboj S. Vesicular drug delivery systems: A novel approach for drug targeting. Int J Drug Deliv 2013;5:121-30.
12. Abdelkader H, Alani AW, Alany RG. Recent advances in non-ionic surfactant vesicles (niosomes): Self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv 2014;21:87-100.
13. Hu C, Rhodes DG. Proniosomes: A novel drug carrier preparation. Int J Pharm 1999;185:23-35.
14. El Maghraby GM, Williams AC. Vesicular systems for delivering conventional small organic molecules and larger macromolecules to and through human skin. Expert Opin Drug Deliv 2009;6:149-63.
15. Fang JY, Yu SY, Wu PC, Huang YB, Tsai YH. In vitro skin permeation of estradiol from various proniosome formulations. Int J Pharm 2001;215:91-9.
16. Gupta A, Prajapati SK, Balamurugan M, Singh M, Bhatia D. Design and development of a proniosomal transdermal drug delivery system for captopril. Trop J Pharm Res 2007;6:687-93.
17. Kirjavainen M, Urtti A, Jääskeläinen I, Suhonen TM, Paronen P, Valjakka-Koskela R, et al. Interaction of liposomes with human skin in vitro – the influence of lipid composition and structure. Biochim Biophys Acta 1996;1304:179-89.
18. Jiao J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Deliv Rev 2008;60:1663-73.
19. Sinko PJ. Martin’s Physical Pharmacy and Pharmaceutical Sciences: Physical Chemical and Biopharmaceutical Principle in the Pharmaceutical Sciences. Philadelphia, PA: Lippincott Williams and Wilkins; 2011. p. 1-1231.
20. Sivaprasad SN, Kumar PL, Srinivas M, Brahmaiah B, Nama S. Proniosome: A novel approach to vesicular drug delivery system. Int J Drug Discov 2013;3:85-90.
21. Rawat AG. Proniosome gel: Anovel topical delivery system. Int J Recent Adv Pharm 2011;1:1-10.
22. Dheeraj N, Deepshikha KP, Nidhi A. Development and characterization of liposomal drug delivery system for gossypin. Int J Pharm Sci Rev Res 2014;27:11-15.
23. Wilkhu JS, Ouyang D, Kirchmeier MJ, Anderson DE, Perrie Y. Investigating the role of cholesterol in the formation of non-ionic surfactant based bilayer vesicles: Thermal analysis and molecular dynamics. Int J Pharm 2014;461:331-41.
24. Yadav K, Yadav D, Saroha K, Nanda S, Mathur P. Proniosomal gel: A provesicular approach for transdermal drug delivery. Pharm Lett 2010;2:189-98.
25. Sahoo RK, Biswas N, Guha A, Kuotsu K. Maltodextrin based proniosomes of nateglinide: Bioavailability assessment. Int J Biol Macromol 2014;69:430-4.
26. Akhilesh D, Faishal G, Kamath JV. Comparative study of carriers used in proniosomes. Int J Pharm Chem Sci 2012;1:164-73.
27. Kumar K, Rai AK. Development and evaluation of proniosomes as a promising drug carrier to improve transdermal drug delivery. Int J Pharm 2011;2:71-4.
28. Kumar SP, Kumar NS, Raghuveer I. Proniosome as a sustained drug delivery system: A review. Int J Pharm 2012;3:27-32.
29. Shukla ND, Tiwari M. Pronisomal drug delivery system-clinical application. Int J Res Pharm Biomed Sci 2011;2:880-7.
30. Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm 2005;59:485-90.
31. Walve JR, Rane BR, Gujrathi NA, Bakaliwal SR, Pawar SP. Proniosomes: A surrogated carrier for improved transdermal drug delivery system. Int J Res Ayurveda Pharm 2011;2:743-50.
32. Jukanti R, Annakula D, Errabelli MR, Bandari S. Provesicular drug delivery systems: An overview and appraisal. Arch Appl Sci Res 2010;2:135-46.
33. Perrett S, Golding M, Williams WP. A simple method for the preparation of liposomes for pharmaceutical applications: Characterization of the liposomes. J Pharm Pharm 1991;43:154-61.
34. Blazek-Welsh AI, Rhodes DG. Maltodextrin-based proniosomes. AAPS Pharm Sci 2001;3:E1.
35. Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level box-behnken design. AAPS Pharm Sci Tech 2007;8:E86.
36. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965;13:238 52.
37. Jain NK. Controlled and Novel Drug Delivery System. 1st ed. New Delhi: CBS Publishers and Distributors; 2003. p. 270.
38. Khandare JN, Madhavi G, Tamhankar BM. Niosomal novel drug delivery system. East Pharm 1994;37:61-4.
39. Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Release 1998;54:149-65.
40. Abd-Elbary A, El-laithy HM, Tadros MI. Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium. Int J Pharm 2008;357:189-98.
41. El-Laithy HM, Shoukry O, Mahran LG. Novel sugar esters proniosomes for transdermal delivery of vinpocetine: Preclinical and clinical studies. Eur J Pharm Biopharm 2011;77:43-55.
42. Couvreur P, Fattal E, Andremont A. Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm Res 1991;8:1079 86.
43. Kumar K, Rai AK. Development and evaluation of proniosome encapsulated curcumin for transdermal administration. Trop J Pharm Res 2011;10:697-703.
44. Consensus Recommendations on Effective Institutional Animal Care and Use Committees. Lab Anim Sci 1987;37 Spec No:11-3.
45. Azeem A, Jain N, Iqbal Z, Ahmad FJ, Aqil M, Talegaonkar S, et al. Feasibility of proniosomes-based transdermal delivery of frusemide: Formulation optimization and pharmacotechnical evaluation. Pharm Dev Technol 2008;13:155-63.
46. Li Q, Li Z, Zeng W, Ge S, Lu H, Wu C, et al. Proniosome-derived niosomes for tacrolimus topical ocular delivery: In vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection. Eur J Pharm Sci 2014;62:115-23.
47. Benipal G. Design, development, and evaluation of proniosomal gel of an antifungal drug ketoconazole. Int J Pharm Sci Rev Res 2015;31:265 272.
48. Prasad V, Chaurasia S. Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis. Mater Sci Eng C Mater Biol Appl 2017;79:168-76.
49. Gupta A. Antidermatophytic activity of miconazole nanoformulation against Trichophyton rubrum. Asian Pac J Trop Dis 2015;5:707-10.
50. Abdelbary GA, Amin MM, Zakaria MY. Ocular ketoconazole-loaded proniosomal gels: Formulation, ex vivo corneal permeation and in vivo studies. Drug Deliv 2017;24:309-19.
51. Sathyavathi A, Hasansathali A, Ilavarasan R. Formulation and evaluation of niosomal in situ gel ocular delivery system of brimonidine tartrate. Int J Pharm Sci Res 2012;2:82-95.
52. Rita B, Lakshmi PK. Preparation and evaluation of modified proniosomal gel for localized urticaria and optimization by a statistical method. J Appl Pharm Sci 2012;2:85-91.
53. Farooqui N, Kar M, Singh RP. Formulation and evaluation of proniosomal gel for transdermal delivery of ketorolac tromethamine. Asian J Pharm 2016;10:394-400.
54. Thomas L, Viswanad V. Formulation and optimization ofthe clotrimazole-loaded proniosomal gel using 32 factorial designs. Sci Pharm 2012;80:731-48.
55. Radha CV, Chowdary CH. Formulation and evaluation of ornidazole proniosomal gel. Indo Am J Pharm Res 2014;4:2657-64.
56. Chandel A, Saroha K, Nanda S. Preparation and evaluation of pronisomal gel of neem seed oil. Int J Pharm Sci Nanotech 2012;5:1780-4.
57. Das MK, Kumar R. Development of curcumin nano niosomes for skin cancer chemoprevention. Int J ChemTech Res 2014-2015;7:747-54.
58. Pal P, Mishra SD. Formulation development and evaluation of antifungal proniosomal gel for topical application. World J Pharm Res 2017;6:656-74.
59. Mehta M, Garg M. Proniosomal gel: A promising drug carrier for boswellic acids. J Med Sci 2015;15:130-4.
60. Lathera V, Sharma D, Pandit D. Proniosomal gel-mediated transdermal delivery of bromocriptine: In vitro and ex vivo evaluation. J Exp Nanosci 2016;11:1044-57.
61. Acharya A,Kumar GB, Ahmed MG, Paudel S. A novel approach to increase the bioavailability of candesartan cilexetil by proniosomal gel formulation: In-vitro and in-vivo evaluation. Int J Pharm Pharm Sci 2016;8:241-6.
62. Badawi A, Elnabarawi MA, Elrehem AR, Fayed BA. Formulation and evaluation of dispersed permethrin proniosomes in powder and microemulsion-based hydrogel bases forthe treatment of scabies. Int J Pharm Pharm Sci 2016;8:221-9.
63. Fouda NH, Abdelrehim RT, Hegazy DA, Habib BA. Sustained ocular delivery of dorzolamide-HCl via proniosomal gel formulation: In-vitro characterization, statistical optimization, and in-vivo pharmacodynamic evaluation in rabbits. Drug Deliv 2018;25:1340-9.
Statistics
39 Views | 0 Downloads
How to Cite
Rajkumar, J., R. Gv, T. Sastri K, and S. Burada. “RECENT UPDATE ON PRONIOSOMAL GEL AS TOPICAL DRUG DELIVERY SYSTEM”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 1, Jan. 2019, pp. 54-61, doi:10.22159/ajpcr.2019.v12i1.28558.
Section
Review Article(s)